Bispecific antibodies: advancing precision oncology.

T cell engagers antibody engineering bispecific antibodies dual-targeted therapy immunotherapy

Journal

Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956

Informations de publication

Date de publication:
29 Aug 2024
Historique:
received: 01 04 2024
revised: 29 06 2024
accepted: 12 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: aheadofprint

Résumé

Bispecific antibodies (bsAbs) are engineered molecules designed to target two different epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets and structure (or format), which can be manipulated to create variable and novel functionalities, including linking immune cells with tumor cells, or dual signaling pathway blockade. Several bsAbs have already changed the treatment landscape of hematological malignancies and select solid cancers. However, the mechanisms of resistance to these agents are understudied and the management of toxicities remains challenging. Herein, we review the principles in bsAb engineering, current understanding of mechanisms of action and resistance, data for clinical application, and provide a perspective on ongoing challenges and future developments in this field.

Identifiants

DOI: 10.1016/j.trecan.2024.07.002 PMID: 39214782
pubmed: 39214782
pii: S2405-8033(24)00142-0
doi: 10.1016/j.trecan.2024.07.002
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests None declared by authors.

Auteurs

Mercedes Herrera (M)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.

Giulia Pretelli (G)

Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

Jayesh Desai (J)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Elena Garralda (E)

Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

Lillian L Siu (LL)

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.

Thiago M Steiner (TM)

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Lewis Au (L)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: Lewis.au@petermac.org.

Classifications MeSH